Pfizer hits the gas pedal in the mRNA flu vaccine development race, inking a $425M investment pact with BioNTech
The mRNA specialists at BioNTech have added another deep-pocket pharma giant to the fold.
Pfizer has stepped up with a $120 million cash commitment — covering an an uncertain mix of upfront cash, equity and near-term research support — to get the German biotech to focus its drug platform on seasonal and pandemic flu. And there’s another $305 million on the line in potential milestone payouts if they can score marketable products.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.